Interview David Segarra – CEO and Co-Founder of aptaTargets

by GENESIS Biomed

David Segarra: “ApToll is an immune modulator to treat ischaemic stroke in the acute phase. We have successfully completed Phase 2a and will soon conduct Phase 2b. We are also testing ApToll for oth...

Read more

Results on the preclinical efficacy of uric acid in ischaemic stroke published

by Fundació Clínic per a la Recerca Biomèdica

The journal Science Translational Medicine has published the results of a preclinical study carried out on rodents that shows the efficacy of uric acid in improving the prognosis of ischaemic stroke. ...

Read more

FreeOx acquires the patent for the drug Ox-01 in the US for ischaemic stroke

by CATALONIA.HEALTH

FreeOx Biotech, a CataloniaBio & HealthTech member, has been granted a patent for its most advanced drug, Ox-01, by the United States Patent and Trademark Office (USPTO). The patent protects the use o...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Ona Therapeutics Raises $86.6 Million Se...

by Ysios Capital

Proceeds to support clinical development of lead first-in-class progra...

Photos Stream